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Cardiovascular disease (CVD) is the leading cause of death worldwide and in the 
United States.  It is estimated  that 17 million people worldwide and over 927,000 
Americans die each year from CVD (Centers for Disease Control and Prevention, 2005; 
World Health Organization, 2006).   While CVD is the leading cause of death in both 
men and women, there are a greater number of females who die of CVD.  In 2004, there 
were 459,096 females compared to 353,100 males in the United States who died from 
CVD (American Heart Association, 2007). 
An elevated blood cholesterol level is a well known risk factor for developing 
CVD (Centers for Disease Control and Prevention, 2005; National Heart Lung and Blood 
Institute, 2006).  The risk for CVD drastically increases for women when they reach 
menopause partly due to an elevation of total cholesterol levels after menopause.  After 
menopause, total cholesterol levels increase putting women at a high risk for developing 
heart disease.  On average, menopause occurs when women are between 45 and 55 years 
of age (World Health Organization, 1996).  Women at this same age have also been 
shown to have a higher percentage of total cholesterol than men of the same age (Ford et 
al., 2003). 
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There are medications which have been approved to help control blood 
cholesterol levels but these medications can have unwanted side effects (National Heart 
Lung and Blood Institute, 2006).  The major types of medications which are generally 
prescribed to lower blood cholesterol particularly LDL-cholesterol include statins, bile 
acid sequestrants, nicotinic acid, fibrates, and ezetimibe (National Heart Lung and Blood 
Institute, 2006).  Some of the side effects of these drugs include abdominal pain, gas, 
constipation, liver abnormalities, gout, and high blood sugar (U.S. Food and Drug 
Administration, 2003; National Heart Lung and Blood Institute, 2006).   
 Hormone replacement therapy (HRT) has also been an option for postmenopausal 
women to relieve menopausal symptoms and reduce cholesterol.  However, the 
cardiovascular benefits of HRT have been questioned after the results of the Women’s 
Health Initiative were announced (National Institute of Health, 2002).  This study found 
that women taking estrogen therapy have an increased risk of stroke and blood clots, and 
women taking estrogen-progestin combined therapy have an increased risk of heart 
attack, stroke, blood clots, and cancer (National Institute of Health, 2002). Therefore, 
postmenopausal women are looking for alternative therapies to help lower cholesterol 
and reduce their CVD risk without the unwanted side effects of HRT and other 
prescription medications.   
 Dietary modifications such as increased fiber, phytoestrogens, and antioxidants 
have previously been shown to reduce cholesterol and CVD risk. (de Kleijn et al., 2002; 
Lucas et al., 2002; Van Horn et al., 2008).  Antioxidants such as anthocyanins, 
resveratrol, and pterostilbene may play a role in reducing the risk of heart disease 
(American Dietetic Association, 2005).  
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 Blueberry is an example of a fruit that is a rich source of antioxidants such as 
anthocyanins, resveratrol, and pterostilbene.  The antioxidant capacity of blueberry is 
among the highest of all fruits and vegetables (Ehlenfeldt and Prior, 2001; Halvorsen et 
al., 2002; Roy et al., 2002).  Previous studies have shown that blueberries may have the 
ability to prevent heart disease, cancer, and improve neural motor function in the aging 
(Joseph et al., 1999).  However, there are a limited number of studies on the effect of 
blueberry on lipid parameters, thus the need for this study. 
The hypothesis of this study was that daily consumption of blueberry dose-
dependently prevents the ovariectomy-induced rise in blood total cholesterol in a rat 
model of postmenopausal hypercholesterolemia.  To test this hypothesis, we had two 
specific aims. 
1. To determine the extent to which a 2.5%, 5%, and 7.5% (w/w) blueberry diet 
reduce both liver and serum total cholesterol, low-density lipoprotein cholesterol, 
and triglyceride levels using the rat model. 
2. To determine if blueberries have an effect on serum levels of lipid hydroperoxide 
and 8-isoprostane, a measure of antioxidative properties. 
This study was designed with the assumption that ovariectomized rats will represent 
postmenopausal women.   
Limitations of this study include:  
1. The polyphenolic compositions of blueberry were not assessed. 







REVIEW OF LITERATURE 
 
Cardiovascular disease (CVD) is the leading cause of death worldwide and in the 
United States.  Worldwide, there are approximately 17 million people who die each year 
from CVD (World Health Organization, 2006) and an estimated 927,000 deaths each year 
in the United States (Centers for Disease Control and Prevention, 2005; World Health 
Organization, 2006).  The combined direct and indirect costs of major CVD and stroke 
for 2008 are 448.5 billion dollars (American Heart Association, 2008).    
Since 1984, the number of female CVD deaths in the United States has exceeded 
the number of males with females representing 52.8 percent of CVD deaths (American 
Heart Association, 2007).  In 2004, there were 459,096 females in the United States who 
died from CVD (American Heart Association, 2007).    
 
Risk Factors for CVD 
There are several risk factors for CVD which can be classified into two groups: 
those which cannot be prevented and those which can be prevented.  Risk factors which 
cannot be prevented include gender, age, and family history.  Men over the age of 45 and 
women over 55 years of age are at increased risk  (National Heart Lung and Blood 
Institute, 2006)  Family history is another risk factor which cannot be controlled.   
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Having a father or brother who was diagnosed with CVD before the age of 55, or a 
mother or sister diagnosed before the age of 65 can increase an individual’s risk of 
developing CVD. 
Other risk factors for developing CVD can often be prevented through lifestyle 
modifications.  This group of risk factors includes being overweight or obese, diabetic, 
smoking cigarettes, sedentary lifestyle, high blood pressure, or high blood cholesterol.   
Obesity is associated with several comorbidities including CVD, type 2 diabetes, 
hypertension, cancer, and sleep apnea and increases the risk for coronary heart disease 
(CHD), heart failure, and sudden death through its impact on the cardiovascular system 
(Poirier et al., 2006).  As adipose tissue accumulates, circulating blood volume, plasma 
volume, and cardiac output must increase causing a dilation of cardiac cavities and 
increases in wall tension resulting in systemic hypertension, pulmonary hypertension, 
CHD, or sudden death (Poirier et al., 2006).  
Diabetes is associated with an increased risk of several complications including 
CVD.   Nearly 21 million Americans currently have diabetes including 9.7 million 
women (American Diabetes Association, 2008).  CVD accounts for about 65% of all 
diabetic deaths, and among diabetic women, deaths from CVD have increased 23% over 
the past 30 years compared to a 27% decrease in women without diabetes (American 
Diabetes Association, 2008).   
Cigarette smoking increases the risk of CVD especially when combined with 
other risk factors.  Smoking causes damage to the lining of the arteries and speeds the 
progression of atherosclerosis (National Heart Lung and Blood Institute, 2008).  Smoking 
has been shown to increase heart rate and blood pressure and reduce blood flow 
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(American Heart Association, 2007).  Smoking increases the level of carbon monoxide in 
the blood, depriving the heart and other tissues of needed oxygen (American Heart 
Association, 2007).  
Physical activity can reduce risk of CVD and type 2 diabetes, and can help control 
weight and blood pressure as well as improving bone density (American Heart 
Association, 2007; Centers for Disease Control and Prevention, 2007).   The American 
Heart Association recommends that adults engage in a minimum of 30 minutes of 
moderate intensity activity at least 5 days each week to promote and maintain health 
(Haskell et al., 2007).  However, the number of sedentary Americans continues to 
increase.  In 2000, 38.5% of adults engaged in no leisure time physical activity, and in 
2005, this number increased to 40.0% (Centers for Disease Control and Prevention, 
2007). 
Nearly one in three adults in the US has high blood pressure which if untreated 
can lead to CVD (American Heart Association, 2007).  Blood pressure is measurement of 
arterial force when the heart beats (systolic pressure) and when the heart is at rest 
(diastolic pressure). High blood pressure is diagnosed when blood pressure is ≥ 140 mm 
Hg systolic pressure or ≥ 90 mmHg diastolic pressure (American Heart Association, 
2007).   Women who are overweight, have a family history of high blood pressure, or 
have reached the age of menopause have an increased risk of developing high blood 
pressure (American Heart Association, 2007).  More than 73 percent of women ages 65 
to 74 have high blood pressure (American Heart Association, 2007). 
High total cholesterol is a major risk factor for developing CVD. When excessive 
amounts of LDL cholesterol are circulating in the blood, excess amounts are deposited in 
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the arteries.  HDL cholesterol is considered protective because HDL cholesterol has the 
ability to carry excess cholesterol back to the liver for recycling.  The risk of CVD is 
increased when LDL cholesterol becomes oxidized by free radicals in the arteries 
(National Heart Lung and Blood Institute, 2006).  Oxidized LDL cholesterol accelerates 
the formation of artery-clogging plaques which stick and accumulate along the lining of 
the artery walls (American Heart Association, 2007).  Free radicals also oxidize 
polyunsaturated fatty acids in cell membranes, initiating additional changes in artery 
walls decreasing blood flow.   
Total serum cholesterol levels can vary greatly depending on age, sex, heredity, 
and current health condition; however a serum cholesterol level less than 200 mg/dL is 
the most desirable.   HDL cholesterol of 60 mg/dL or more is considered protective.  
Having high triglycerides can also place an individual at increased risk of CVD.  A 
desirable range for triglycerides is less than 150 mg/dL  (American Heart Association, 
2007).   A decrease in total cholesterol of just 10% can reduce coronary artery disease 
risk by 30% (Centers for Disease Control and Prevention, 2005).  
 
Menopause and CVD 
In the United States, CVD is the main category of hospitalization discharge for 
women and is the cause of 39% of all female deaths (American Heart Association, 2007). 
While CVD risk increases with age for both men and women, the risk drastically 
increases for women when they reach menopause.   On average, menopause occurs when 
women are between 45 and 55 years of age (World Health Organization, 1996).  This 
increased CVD risk may be related to both metabolic and hormonal changes.  After 45 
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years of age, women are shown to have higher total cholesterol than men of the same age 
(Ford et al., 2003).   
Some CVD risk factors such as hypertension, hypertriglyceridemia, diabetes and 
low HDL- cholesterol may be stronger risk factors for women than for men (Eaker et al., 
1993; Vitale et al., 2007).  Menopause is associated with the development of 
hypertension, central obesity, and dyslipidemia therefore putting postmenopausal women 
at an increased risk for CVD (de Kleijn et al., 2002).  After menopause, there is often an 
increase in total cholesterol and LDL cholesterol putting women at increased risk for 
developing CVD (Stevenson et al., 1993; Post et al., 1996; Vitale et al., 2007). 
For postmenopausal women, the increased risk of CVD has been attributed to 
ovarian hormone deficiency (Gorodeski, 2002; Chamberlain et al., 2008).  Estrogen 
deficiency, whether through natural or surgically induced menopause, is an important risk 
factor for CVD.  As a result of decreased estrogen, menopausal transition may act 
synergistically with gene variations to alter lipoprotein levels (Chamberlain et al., 2008).   
The Atherosclerosis Risk in Communities (ARIC) study was a longitudinal study of 
8,710 women aged 45-64 years that was conducted to determine an association between 
menopausal status and specific gene polymorphisms, including apolipoprotein E and 
lipoprotein lipase genes.  Postmenopausal women had significantly higher LDL 
cholesterol, a higher frequency of obesity and overweight, were more commonly diabetic, 
and were also more likely to be taking cholesterol lowering medication and hormone 
replacement therapy than premenopausal women (Chamberlain et al., 2008).  
Chamberlain and colleagues did not find a gene polymorphism which was modified by 
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menopausal status but determined that the decrease in estrogen may independently affect 
lipoprotein concentration (Chamberlain et al., 2008).    
Post and colleagues (1996) investigated changes in coronary risk factors 
associated with menopause.   They enrolled 610 women from the Framingham Offspring 
Study who were premenopausal at baseline, not on estrogen replacement, and were 40-57 
years at the time of follow-up.  These women were classified as premenopausal or 
postmenopausal if they had undergone natural menopause since the baseline exam eight 
years previous.   Results of the follow-up physical exam indicated that in the 
postmenopsaul group there was a greater increase in total cholesterol and LDL 
cholesterol (Post et al., 1996).  
In a prospective study investigating the CVD risk of women at the age of 53 
years, Kuh and colleagues (2005) enrolled 1303 women aged 53 years and classified 
them into five groups: premenopausal, perimenopausal, postmenopausal, hysterectomy, 
or hormone replace therapy user.  The purpose of this study was to compare the changes 
in CVD risk factors such as blood pressure, central and total obesity, total cholesterol, 
HDL cholesterol, LDL cholesterol, and glycosolated hemoglobin (HbA1c) among 
groups.   Advantages to this study were that the women were all of equal age and 
previous data had been collected at age 43 years.  Results of this study showed that 
postmenopausal and hysterectomized women had the highest levels of metabolic risk 
factors (Kuh, et al., 2005).    
The relationship between menopause and coronary heart disease (CHD) risk 
factors were assessed in a cross-sectional study of 1,684 French women aged 45-65 years 
(Tremollieres et al., 1999).  Women were assigned to either a postmenopausal group or 
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perimenopausal group.    All women were given a physical exam including blood 
samples and then asked to complete a questionnaire relating to CHD risk factors.  The 
postmenopausal group had a significantly higher rate of hypertension and a higher 
prevalence of obesity and sedentary lifestyle.  Elevated serum total cholesterol, LDL 
cholesterol, and triglycerides were also significantly more frequent in the postmenopausal 
group (Tremollieres et al., 1999). 
A proposed mechanism for the increased CVD risk among postmenopausal 
women may be related to lipid peroxidation.  Postmenopausal women have higher levels 
of lipid peroxidation than premenopausal women indicating that lipid peroxidation may 
be the mechanism responsible for the increased CVD risk (Castelao and Gago-
Dominguez, 2008).   
In summary, menopause puts women at an increased risk of CVD due to an a 
increase in several CVD risk factors including hypertension, abdominal obesity, and 
dyslipidemia (Post et al., 1996; Tremollieres et al., 1999; Kuh et al., 2005).  After 
menopause there is increase in total cholesterol and LDL cholesterol putting women at 
increased risk for developing CVD (Stevenson et al., 1993; Post et al., 1996; Vitale et al., 
2007). 
 
Treatment options for lowering cholesterol 
  
 Since the 1940s, hormone replacement therapy (HRT) has been shown to be 
effective in reducing many menopausal symptoms and has also been reported to have 
positive effects on bone, cholesterol, and CVD risk (Kim  et al., 1994).  Menopause 
occurs when ovarian function begins to decline producing less estrogen.  With a 
decline in estrogen, many women begin experiencing adverse menopausal symptoms 
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and are also at an increased risk for chronic diseases such as CVD and osteoporosis.  
In the 1940s, the US Food and Drug Administration granted approval of 
diethylstilbestrol and conjugated equine estrogens to replenish postmenopausal 
estrogen levels and treat menopausal symptoms (Stefanick, 2005).  In the 1970s, 
progestin was combined with estrogen because women using estrogen alone were 
found to have an increased risk of developing uterine cancer (American Medical 
Association, 2005).    
In 1991, the National Heart, Lung, and Blood Institute and the National 
Institute of Health sponsored the Women’s Health Initiative (WHI) to investigate the 
effects of HRT.  This was an observational study, a community prevention study, and 
a two part clinical trial which included a total of 161,000 postmenopausal women 
(National Institute of Health, 2002). The first part of the clinical trial included 16,608 
women taking estrogen-progestin combined therapy or a placebo.  The second part 
included 10,739 women taking estrogen-alone therapy or a placebo.  Both components 
of the clinical trial were stopped early when researchers found that the risks to 
participants outweighed the benefits of treatment.  Estrogen-alone therapy put women 
at an increased risk of stroke and blood clots.  Women taking estrogen-progestin 
combined therapy were not only put at an increased risk of stroke and blood clots, but 
were also at an increased risk of developing heart disease and breast cancer. 
In 2003, the results of a sub-study of the WHI, the Women’s Health Initiative 
Memory Study (WHIMS), announced its findings that older women taking 
combination hormone therapy have twice the risk of developing dementia, including 
Alzheimer's disease, compared to women taking the placebo (National Institute of 
 12 
Aging, 2003).  Then, in 2004, investigators of the WHIMS announced further findings 
that estrogen-alone hormone therapy could also increase an older woman’s risk for 
developing dementia (National Institute of Health and Aging, 2004).  Researchers 
found that women taking estrogen-alone therapy had a 49% greater risk for developing 
dementia than the group taking the placebo.  
To determine if the results of the Women’s Health Initiative had an effect on 
the current use of hormone replacement therapy, Kelly et al. (2005) conducted a 
survey of 3853 women who were 50 years of age and older. Participants in this study 
were interviewed to estimate current medication use.  The findings from this survey 
indicated that there is a large decline in the use of hormone therapy by 
postmenopausal women after the results of the WHI were announced (Kelly et al., 
2005).  
There are medications that can be prescribed to help improve cholesterol levels 
which include statins, bile acid sequestrants, nicotinic acid, fibrates, and ezetimibe 
(National Heart Lung and Blood Institute, 2006; American Heart Association, 2007). 
Statin drugs include:  atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Mevacor), 
pravastatin (Pravachol), simvastatin (Zocor), and rosuvastatin (Crestor).  Statins lower 
cholesterol by blocking the action of the liver enzyme HMG Co-A reductase thus 
reducing the synthesis of cholesterol (National Heart Lung and Blood Institute, 2006).  
Statins can also offer antiatherosclerotic effects beyond improvement of plasma lipids. 
These benefits include stabilizing plaques, improving vascular relaxation, and promoting 
new vessel formation (Ikeda and Shimada, 2001).  Statins may also inhibit both prepro-
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endothelin (ET-1) contraction and DNA synthesis in vascular smooth muscle (Mraiche et 
al., 2005).   
Although statins can be effective at improving cholesterol, they can produce side 
effects such as abdominal pain, gas, and constipation (American Heart Association, 
2008).  Individuals taking statins can also develop liver and muscle problems (National 
Heart Lung and Blood Institute, 2006).  Statins may also produce adverse effects to the 
oral cavity.  A recent study by Cruz and colleagues (2008) found that statin use was 
associated with oral symptoms such as dryness and itching of the tongue and lips and 
increased coughing (Cruz et al., 2008).   
Bile acid sequestrants exert lipid lowering effects by binding to bile acids and 
promoting their excretion in the feces causing the liver to use cholesterol for the synthesis 
of new bile acids. This effectively reduces LDL-cholesterol levels.  Bile acid sequestrants 
include:  colestipol (Colestid), colesevelam (Welchol), and cholestyramine (Questran).  
Bile acid sequestrants can also be effective in lowering LDL-cholesterol by 10 to 20 
percent; however these drugs have been shown to cause gas, bloating, and constipation 
(National Heart Lung and Blood Institute, 2006).  Bile acid sequestrants can also raise 
triglyceride levels (American Heart Association, 2008).   
Nicotinic acid or niacin is a water soluble B vitamin which improves lipoprotein 
levels.   Nicotinic acid is thought to improve lipid levels by decreasing fatty acid 
mobilization and inhibiting synthesis of triglycerides which leads to increased 
intracellular apo B degradation and reduced secretion of VLDL and LDL particles (Ganji 
et al., 2003).  Nicotinic acid can lower LDL cholesterol by 10 to 20 percent and reduce 
triglycerides by 20 to 50 percent (National Heart Lung and Blood Institute, 2006) and can 
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also increase HDL cholesterol (Birjmohun et al., 2005).  Nicotinic acid is available in 
three forms: immediate release, timed release, and extended release (National Heart Lung 
and Blood Institute, 2006).  Although nicotinic acid can help lower cholesterol levels, 
individuals often experience bothersome side effects such as flushing or hot flashes 
which occur from dilation of the blood vessels (National Heart Lung and Blood Institute, 
2006).  Nicotinic acid can also cause a variety of gastrointestinal side effects such as 
nausea, indigestion, gas, vomiting, and diarrhea, and individuals must be closely 
monitored due to a variety of serious side effects such as liver abnormalities, gout, and 
high blood sugar (National Heart Lung and Blood Institute, 2006).   
Fibrates are a class of cholesterol lowering drugs that are primarily effective at 
reducing triglycerides and may increase HDL cholesterol (Birjmohun et al., 2005).  The 
effects of fibrates on lipid metabolism are mostly mediated through the activation of 
peroxisome proliferator-activated receptors (PPARα) improving the plasma transport rate 
of lipoproteins (Watts and Dimmitt, 1999).  Individuals taking fibrates generally 
experience a 20 to 50 percent reduction in triglycerides and an increase of 10 to 15 
percent in HDL cholesterol (National Heart Lung and Blood Institute, 2006).  However, 
individuals taking fibrates are put at increased risk of developing cholesterol gallstones, 
and fibrates can interfere with other medications (National Heart Lung and Blood 
Institute, 2006).  
Ezetimibe can also be effective at controlling cholesterol by blocking the 
absorption of biliary and dietary cholesterol within the intestinal tract.  Ezetimibe 
localizes at the brush border of the small intestine and decreases cholesterol uptake into 
the enterocytes (Nutescu and Shapiro, 2003).  Ezetimibe can reduce LDL cholesterol by 
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15 to 20 percent (Nutescu and Shapiro, 2003) and co-administering with a statin can 
increase its effectiveness (Lipka, 2003).  However, ezetimibe can cause side effects such 
as abdominal pain and fatigue (U.S. Food and Drug Administration, 2003).    
Although cholesterol lowering medications may be effective, these medications 
do not come without unwanted side effects.  They are also expensive and often require 
lifelong treatment (Hu, 2005).  
   
Dietary Modifications 
 
 Because of the risks and unwanted side effects associated with hormone therapy 
and other medications, postmenopausal women are looking for alternative therapies to 
help lower cholesterol and reduce their CVD risk.  There have been many studies 
conducted which have shown that dietary modifications such as increased fiber intake, 
phytoestrogens, antioxidants, and polyphenols such as anthocyanins, resveratrol, and 
pterostilbene may improve cholesterol and reduce CVD risk (American Dietetic 




An increased intake of dietary fiber may help prevent CVD (Marlett et al., 2002; 
American Heart Association, 2007).  The adult treatment panel III recommends viscous 
(soluble) fiber as a therapeutic dietary option to enhance lowering of LDL cholesterol 
(National Cholesterol Education Program. Expert Panel on Detection Evaluation and 
Treatment of High Blood Cholesterol in Adults, 2002).  Fiber is an indigestible 
carbohydrate and is present in plant foods such as grains, vegetables, and fruits.  Fiber is 
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classified into two groups, soluble fiber and insoluble fiber.  Soluble fiber, or viscous 
fiber, is found in foods such as oats, beans, peas, seeds, barley, citrus fruits, strawberries, 
blueberries, and apple pulp.  Insoluble fiber is found in foods such as whole-wheat 
breads, cereals, rye, rice, barley, vegetables, and apple skin.   
 Consumption of dietary fibers, especially viscous fibers, has been associated with 
lower blood cholesterol levels and improved blood glucose and insulin levels (Marlett et 
al., 2002; Galisteo et al., 2008).  These benefits show that fiber consumption may help 
prevent CVD and diabetes.  To help reduce cholesterol, the American Heart Association 
recommends eating foods that contain both soluble and insoluble fiber (American Heart 
Association, 2007).  Current recommendations for dietary fiber consumption are 21-38 
grams/day (American Dietetic Association, 2006). 
The cholesterol lowering benefits of fiber may be related to its viscosity and 
fermentability (Marlett et al., 2002).  As food is digested, fiber interferes with bile acid 
absorption and bile is excreted from the body.  LDL cholesterol is then removed from the 
blood and new bile acid is synthesized to replace bile acids lost in the stool (Marlett et al., 
2002).     
High fiber intake has been linked to reduced cholesterol and CVD risk in 
several studies (Jenkins et al., 2003; Galisteo et al., 2008).  A study by Queenan et al, 
(2007) randomly assigned 75 hypercholesterolemic males and females to receive 
either 6 grams per day of concentrated oat-glucan, a fermentable fiber or dextrose as 
control.  After six weeks, researchers found that the treatment group had a significant 
reduction in total and LDL cholesterol (Queenan et al., 2007). 
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The efficacy of a dietary portfolio including viscous fibers was compared to 
statin treatment in a randomized parallel study of 46 hyperlipidemic adults (Jenkins et 
al., 2003).  Participants were assigned to a low fat diet (control), low fat diet plus 20 
mg lovastatin (statin group), or a low fat diet including plant sterols, viscous fibers, 
soy protein and nuts (dietary portfolio group).  After 4 wks of treatment, LDL 
cholesterol concentrations decreased by 8.5%, 33.3%, and 29.6% in control, statin, 
and dietary portfolio group, respectively.  There was no significant difference in 
cholesterol reduction between the dietary portfolio group and the statin group.  These 
results indicated that dietary modifications which include viscous fibers and vegetable 
proteins such as soy and nuts may have a similar ability to reduce LDL cholesterol to 
treatment of a statin drug (Jenkins et al., 2003). 
 A fiber rich diet may also help reduce blood pressure in adults with 
hypercholesterolemia (Behall et al., 2006).  Insoluble fiber (whole wheat and brown 
rice) and soluble fiber (barley) were found to reduce diastolic and mean arterial blood 
pressure in hypercholesterolemic adults (Behall et al., 2006). 
The effects of soluble fiber intake on CVD risk was assessed in a study of 9776 
adults who participated in the National Health and Nutrition Examination Survey I 
(NHANES I) Epidemiologic Follow-up Study.  Baseline data from NHANES I was 
collected between 1971 and 1975 and included dietary assessments, medical 
examination, and laboratory tests.  Follow-up data was collected 19 years later and 
revealed dietary fiber, particularly water-soluble fiber, was significantly associated 
with CVD incidence and mortality (Bazzano et al., 2003).  Individuals consuming 
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more than 4 grams of soluble fiber per 1735 kcals have a 15% reduced risk of CHD, 
10% reduced risk of CVD, and a 12% lower CVD mortality (Bazzano et al., 2003).   
The effects of fiber on metabolic syndrome have been investigated (Galisteo et 
al., 2008).  Metabolic syndrome is the term to describe a cluster of abnormalities 
which increase an individual’s risk of CVD.  Metabolic syndrome includes central 
obesity, low concentrations of plasma HDL cholesterol, high levels of triglycerides, 
hypertension, hyperglycemia, and insulin resistance (Galisteo et al., 2008).  Dietary 
fiber was found to improve all metabolic syndrome abnormalities including improved 
lipids, weight, and insulin sensitivity (Galisteo et al., 2008).     
In a recent study, dietary fiber from cocoa was found to help reduce lipids in 
hypercholesterolemic rats (Lecumberri et al., 2007).  Researchers in this study tested 
the cholesterol lowing effects of 165g cocoa fiber /kg diet of which 80% was soluble 
fiber.   Rats which were fed a diet containing cocoa fiber had a significant reduction in 
LDL cholesterol, total serum cholesterol, and triglycerides. 
 
      Antioxidants 
Oxidative stress is linked to the development of hypertension, hyperglycemia, 
and hyperlipidemia (Kaliora and Dedoussis, 2007).  Oxidative stress induced by 
reactive oxygen species (ROS) initiates plaque formation through the oxidation of the 
LDL cholesterol (Rao, 2002).  Macrophages inside the arterial wall take up the 
oxidized LDL and cause the formation of plaque (Rao, 2002).  This plaque formation 
accumulates and sticks to arterial lining causing atherosclerosis.  Consuming foods 
high in antioxidants may lower CVD risk by preventing the oxidation of cholesterol.   
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In a double-blind and placebo-controlled study, 2002 patients with coronary 
atherosclerosis were enrolled to investigate the link between the antioxidant vitamin E 
(α-tocopherol) and CVD progression (Stephens et al., 1996).  Individuals were 
randomized to one of three groups: 800 IU/ day α-tocopherol capsules, 400 IU/ day α-
tocopherol capsules, or placebo capsules.  Plasma α-tocopherol concentrations 
increased in the both treatment groups but did not change in the placebo group. α-
tocopherol treatment significantly reduced the risk of the non-fatal myocardial 
infarction (Stephens et al., 1996).   
Devaraj and colleagues (2007) investigated the effects of a high dose vitamin E 
supplement (1200 IU/day for 2 years) on biomarkers of oxidative stress and 
inflammation in a double blind, randomized, placebo controlled trial.  The vitamin E 
form RRR- α-tocopherol was used in this study because it has been shown to exhibit 
both antioxidant and anti-inflammatory activity (Devaraj et al., 2007).  There were no 
changes in the lipid profile of treatment groups compared to placebo, however plasma 
α-tocopherol levels were significantly higher in the group receiving RRR- α-
tocopherol supplementation, and supplementation significantly reduced LDL 
oxidation (Devaraj et al., 2007). 
In a study evaluating the beneficial effect of tomatoes, a rich source of the 
antioxidant, lycopene on coronary heart disease (CHD), Bose and Agrawal (2007) 
investigated the lipid peroxidation rate of serum enzymes such as superoxide 
dismutase, glutathione peroxidase, and glutathione reductase, as well as the lipid 
profile of participants with CHD or an age-matched control group.  After 60 days of 
tomato supplementation, participants showed a significant improvement of serum 
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enzyme levels and decreased lipid peroxidation rate compared to the control group.  
However, there were no significant changes in lipid profile (Bose and Agrawal, 2007).  
The best way to add antioxidants to the diet is to consume generous servings of 
fruits and vegetables daily.  Adebawo and colleagues (2006) studied the effects of a 
diet rich in fruits and vegetables on CVD risk factors.  These researchers enrolled 20 
African individuals with hypertension and looked at the effects of consuming a diet 
rich in locally grown fruits and vegetables on CVD risk factors.   They found that 
eating fruits and vegetables was associated with decreases in serum triglycerides, total 
cholesterol, and LDL cholesterol, thus reducing CVD risk factors. 
 
Phtyoestrogens 
Phytoestrogens are naturally occurring plant compounds with similar structures 
and function to that of estradiol.  Phytoestrogens have been found to promote health and 
may help reduce CVD risk and offer a variety of postmenopausal benefits (Lissin and 
Cooke, 2000).  Studies on phytoestrogens have reported decreases in postmenopausal 
symptoms and  a decreased  incidence of osteoporosis and breast cancer (Setchell and 
Cassidy, 1999; Lissin and Cooke, 2000).  The three most common phytoestrogens and 
their sources include isoflavones (soybeans), lignans (flaxseed), and coumestans (alfalfa 
sprouts) (Lissin and Cooke, 2000).   
A cross-sectional study of 939 postmenopausal women investigated the 
association between the intake of isoflavones and lignans and CVD risk factors such 
as blood pressure, waist-hip ratio, and plasma lipoprotein levels (de Kleijn et al., 
2002).  CVD risk factors such as waist-hip ratio and plasma triglyceride levels were 
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lower in women consuming more isoflavones and lignans (de Kleijn et al., 2002).  The 
results of this study indicate that phytoestrogens may have the potential to reduce 
CVD risk factors in postmenopausal women (de Kleijn et al., 2002).  
To determine the effects of soy foods on markers for CVD and osteoporosis, 
forty-two postmenopausal women were asked to consume three daily servings of 
whole soy foods containing approximately 60 mg/d of isoflavones for 12 weeks 
(Scheiber et al., 2001).  Results of this study indicate that 60 mg/d of isoflavones may  
result in reductions in several key clinical risk factors for CVD and osteoporosis in 
postmenopausal women (Scheiber et al., 2001).  Lucas et al. (2003) demonstrated that 
soy isoflavones could help reduce CVD risk factors and prevent hypercholesterolemia 
in a hamster model of postmenopausal hypercholesterolemia.  These studies show that 




Polyphenols are a subclass of antioxidants which are present in many fruits and 
vegetables.   Polyphenols such as anthocyanins, resveratrol, and pterostilbene are 
abundant in berries, grapes, and wine and have been studied to determine their 
relationship to CVD and other chronic diseases. 
Anthocyanins are antioxidant compounds which make up the bright blue, 
violet, red, and purple colors of fruits and vegetables.   Anthocyanins are particularly 
rich in soft fruits such as red grapes, blueberries, raspberries, and cranberries.   The 
cardioprotective benefits of grape polyphenols were investigated in a single-blind, 
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crossover study design of  24 pre- and 20 post-menopausal women (Zern et al., 2005).  
Subjects were asked to consume 36 g/day grape powder or placebo for 4 weeks 
followed by a 3 week washout period, then alternate treatments.   They found that the 
grape powder significantly reduced plasma triglycerides, LDL cholesterol, and urinary 
isoprostane concentrations.  
Resveratrol is found in grapes, berries, and peanuts.  It is the heart healthy 
antioxidant found in red wine and may reduce the risk of heart disease and cancer 
(American Dietetic Association, 2005).  Curtis and colleagues (2005) investigated the 
effects of alcohol free red wine on arterial thrombosis in order to determine if the 
beneficial effects of red wine were related to wine consumption or the alcohol.   They 
found that the benefits from the red wine were related to polyphenols in the wine and not 
the alcohol (De Curtis et al., 2005). 
Pterostilbene has been shown to have lipid lowering effects in hamsters (Rimando 
et al., 2005).   The researchers first investigated the effects of resveratrol and the 
analogues pterostilbene, piceatannol, and resveratrol trimethyl ether on the peroxisome 
proliferator-activated receptor α- isoform (PPARα).  PPARα plays a role in fatty acid and 
lipid metabolism and can increase the β-oxidation of fatty acids and cause a reduction in 
triglycerides and VLDL cholesterol.   PPARα can also lead to an increase in HDL 
cholesterol by causing an induction of hepatic apolipoprotein A-I and A-II expression.   
Results of their analysis indicated that of the four stilbene analogues, pterostilbene had 
the highest effect on PPARα , and its results were higher than cirofibrate, a 
hypolipidemic drug.  The researchers then expanded their study and randomly assigned 
eighteen 7-8 week old male golden Syrian hamsters to receive a high fat control diet or 
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high fat diet fortified with pterostilbene for 21 days.  Results of this study indicated that 
the pterostilbene fed hamsters had 29% lower LDL cholesterol and 7% higher HDL 
cholesterol than the control group (Rimando et al., 2005).   
 
Blueberries 
 The antioxidant capacity of blueberries is among the highest of fruits and 
vegetables (Ehlenfeldt and Prior, 2001; Halvorsen et al., 2002; Roy et al., 2002).  
Blueberries contain anthocyanins, resveratrol, and pterostilbene.  Although there have 
been many studies which have shown cardiovascular benefits from eating a diet rich in 
fruits and vegetables, there have been a limited number of studies showing the relation of 
blueberries to CVD.   However, there have been many recent studies which have shown 
benefits of blueberry consumption and improved brain function (Andres-Lacueva et al., 
2005;  Sweeney et al., 2002).    
Joseph et al. (1999) conducted a study to determine if fruits with high antioxidant 
activity, including blueberry, could reverse age-related declines in neural and behavioral 
functions.  These researchers used forty 19-month old male rats which were assigned to 
one of four treatment groups: control, 1.48% strawberry, 0.91% spinach, or 1.86% 
blueberry.  The amounts of fruits were based on ORAC activity so each diet provided 
equivalent antioxidants.  Rats were fed their assigned diet for 8 weeks before neural and 
psychomotor behavior testing.  Researchers found that these fruit extracts were able to 
prevent age-related neuronal and behavioral dysfunctions with blueberry supplementation 
showing the greatest effect on reversing the deleterious effects of aging on calcium 
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homeostasis. The blueberry fed rats were also the only group to show reversals in motor 
behavioral deficits (Joseph et al., 1999).  
In a study looking at the effects of blueberry on memory, researchers examined 
the effects of blueberry consumption using a rat model to determine if the polyphenols 
from a 2% blueberry supplemented diet could be found in brain areas corresponding with 
cognitive performance.  The researchers found that several anthocyanins were found in 
the cerebellum, cortex, hippocampus or striatum of the rats receiving the blueberry diet.  
The findings from this study suggest that there is a relationship between learning and 
memory in rats fed a blueberry supplemented diet (Andres-Lacueva et al., 2005). 
Sweeny and colleagues (2002) investigated the effects of blueberry on ischemia-
induced brain damage.  Researchers fed a 14.3% blueberry diet to male Long-Evans rats 
for six weeks before ligation of the left common carotid artery followed by hypoxia to 
induce stroke.  One week after the simulated stroke, researchers determined that rats on 
the blueberry diet had only a 17 ± 2% loss of neurons to the ischemic hippocampus 
compared to a loss of 40 ± 2% in the control group.  This study shows that the 
consumption of blueberries may help protect against ischemia-induced brain damage, and 
may help improve stroke outcomes (Sweeney et al., 2002).   
While these previously mentioned studies were looking at benefits from blueberry 
other than cardiovascular benefits, these studies were able to show the potential of 
blueberry to help protect against chronic degenerative diseases.   Consuming a diet rich in 
antioxidants has been recommended as a way to help prevent chronic diseases such as 
CVD.   Eating a diet rich in blueberries has been found to increase serum antioxidant 
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status, and therefore may help prevent the development of cardiovascular disease (Kay 



























Animals and Treatment Groups 
Sixty two 5-month old Sprague-Dawley rats (Harlan Sprague-Dawley Inc., 
Indianapolis, IN) were housed two per cage in an environmentally controlled laboratory 
at the Laboratory for Animal Research at Oklahoma State University, Stillwater, OK.  
Guidelines for the ethical care and treatment of animals from the Animal Care and use 
Committee at Oklahoma State University were strictly followed.  The rats were 
acclimated for three days and were either sham-operated (SHAM; 1 group) or 
ovariectomized (OVX; 4 groups) with 12-13 rats per group.  After surgery, rats were 
assigned to one of four dietary treatments for ninety days:  control diet (SHAM and one 
OVX group), 2.5% blueberry diet (OVX + 2.5%), 5% blueberry diet (OVX + 5%), or 
7.5% blueberry diet (OVX + 7.5%).  Experimental groups are shown in Figure 1.  The 
compositions of the experimental diets are shown in Table 1.  Diet was restricted to the 
mean food intake of the SHAM control group and all rats had free access to deionized 
water.  Food intake was monitored every three days and body weight was monitored 
weekly.   
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Animal Necropsy and Processing of Tissue Samples 
At the end of the ninety day treatment period, rats were fasted for 12 hours and 
placed in metabolic cages.  The rats were then anesthetized with a mixture of ketamine 
hydrochloride (100 mg/kg body weight) and xylazine (5 mg/kg body weight) and bled 
from the abdominal aorta.  Blood samples were collected and centrifuged using the Jouan 
CR3i tabletop centrifuge (Winchester, VA).  Samples were centrifuge at 4000 rpm for 20 
minutes at 4°C to separate serum.  Aliquots of serum were kept frozen at -80° C until 
analyzed.   
The liver was immediately removed, rinsed with ice-cold saline solution, and total 
liver weight was recorded.   The liver was then placed in a sealed container and kept 
frozen at -80°C until analysis.  The uterus and spleen were removed, weighed, and 




Serum total cholesterol, HDL cholesterol, and triglycerides were measured using 
the Alfa Wassermann clinical chemistry analyzer (West Cadwell, NJ).  Other clinical 
parameters such as albumin (ALB), alkaline phosphatase (ALP), blood urea nitrogen 
(BUN), calcium, creatinine, magnesium, phosphorus, and total protein were also 
analyzed using the Alfa Wassermann clinical chemistry analyzer (West Cadwell, NJ).  
The analyzer was calibrated using Gemcal reference serum (Alfa Wassermann; West 
Caldwell, NJ).  Lipid concentrations were determined using commercially available kits 
and checked with a high and low quality control (Alfa Wasserman; West Caldwell, NJ).  
The tests were performed according to the manufacturer’s instructions. 
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 Serum total cholesterol was determined using a reagent containing cholesterol 
esterase.  The cholesterol esterase is used to release cholesterol from its esters producing 
hydrogen peroxide.  When combined with 4-aminoantipyrine (AAP) and p-
hydroxybenzoic acid, a red color is produced which is directly proportional to cholesterol 
concentration and measured photometrically at 505 nm.   
 HDL cholesterol was measured using a detergent which solubilizes HDL 
lipoprotein particles allowing HDL cholesterol to react with cholesterol esterase and 
cholesterol oxidase.  In the presence of a chromogen, a color is produced which is 
directly proportional to HDL cholesterol concentration and can be determined by 
measuring the increase in absorbance bichromatically at 592/692 nm. 
 Triglycerides were measured using a reagent which causes a series of enzymatic 
reactions resulting in the production of H2O2.  The H2O2  reacts with the p-chlorophenol 
and AAP catalyzed by peroxidase producing a red-colored complex which is directly 
proportional to triglyceride concentration and can be measured at an absorbance of 505 
nm. 
 
Liver lipid parameters 
 Total liver lipids were determined using the Folch gravimetric method (Folch et 
al., 1957).  Approximately two grams of liver samples were homogenized, placed in 50 
ml centrifuge tubes, and extracted with 25 ml chloroform: methanol (2:1u/u) mixture.  
Sodium chloride solution (0.73%) was added to the chloroform: methanol mixture.  
Tubes were vortexed and left standing until two phases were distinctly separated.  The 
top aqueous layer was aspirated, and the bottom organic layer was transferred to a 25 ml 
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volumetric flask and diluted to the mark with chloroform: methanol (2:1).  An aliquot of 
2 ml of the organic layer was used for cholesterol analysis and the remainder of the 
solution was poured into pre-dried and pre-weighed aluminum pans for total lipid 
analysis.   
The filled aluminum pans were placed under a fume hood overnight to allow the 
solvent to evaporate.  The pans were then placed in a 100°C oven for 1 hour and cooled 
in a dessicator for 30 minutes.  The pans were then weighed and recorded to determine 
total lipid content.   
 A 2 ml aliquot of lipid extracted by the Folch method was used to determine liver 
total cholesterol according to the color reaction method by Searcy and Bergquist (1960).  
The lipid extract was placed in duplicate into 25 x 125 mm culture tubes and evaporated 
under nitrogen gas.  Once dried, 15 ml saponification solution (15% alcoholic KOH 
solution and 3% pyrogallic acid in 90% ethanol) was added to all tubes.  Tubes were then 
placed in a shaking water bath for 10 minutes at 88°C.   After tubes were cooled, 5 ml 
distilled water and 10 ml hexane were added to the tubes.  Tubes were vortexed and left 
standing to separate.  An aliquot of 5 ml supernatant was pipetted into another 25 x 125 
mm tube and placed under the fume hood to evaporate.  Once tubes were dry, 400 µl 
acetone: ethanol (1:1), 6 ml saturated  FeSO4-7H2O in glacial acetic acid and 2 ml 
concentrated sulfuric acid were added to each tube.  Tubes were vortexed, cooled, and 






 Lipid hydroperoxide (LPO) was assessed using a commercially available kit from 
Cayman Chemical (Ann Arbor, MI) to measure the hydroperoxides utilizing 
reduction/oxidation reactions with ferrous ions.  The assay was performed using an 
extraction method with chloroform to prevent an overestimation of LPO.  Serum samples 
were aliquoted into glass test tubes and prepared according to manufacturer’s 
instructions.  An equal amount of 600µl Extract R (crystalline solid saturated in ethanol) 
was added to each sample and vortexed.  One ml of cold chloroform was then added to 
each tube, vortexed, and centrifuged at 1,500 x g for 5 minutes.  The bottom chloroform 
layer was pipetted, transferred to another test tube, and stored on ice.  An aliquot of 
chloroform-methanol solvent (1:1, v/v) was added to 500 µl of each sample followed by 
50 µl of chromogen.  Three hundred µl of samples were pipetted into a 96-well plate and 
absorbance at 500 nm was measured.    
   
8- Isoprostane 
 8-isoprostane was determined using the competitive enzyme immunoassay 
(Cayman Chemical, Ann Harbor, MI).  Because 8-isoprostane and 8-isoprostane-
acetylcholinesterase (AChE) compete for 8-isoprostane-specific rabbit antiserum binding 
sites, this assay measures the amount of 8-isoprostane-acetylcholinesterase (AChE) or 8-
isoprostane tracer that is able to bind to rabbit antiserum as this is inversely proportional 
to the concentration of 8-isoprostane of the sample.  Fifty µl of serum or standards were 
pipetted into the wells of a 96-well plate which was supplied with the assay kit.  Samples 
were assayed in duplicate and 50 µl of 8-isoprostane AChE tracer and 50 µl  8-
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isoprostane antiserum were added to each sample well.  The plate was incubated for 18 
hours at room temperature.  Wells were then emptied and washed five times with wash 
buffer.  Ellman’s Reagent was prepared and added to each well.  The plate was covered 
and placed on an orbital shaker for 60 minutes to develop in the dark before being read at 








Food intake, body and tissue weights   
Food intake, body and tissue weights are presented in Table 2.  Food intake 
among treatment groups averaged approximately 14 g per day.  There was no significant 
difference in food intake between groups as rats were pair-fed to the mean food intake of 
the sham group.  Because rats were randomly assigned to treatment groups based on body 
weight, there was no significant difference in initial body weight.  However, after 90 days 
of treatment, the weight of the sham control group was significantly lower than all the 
OVX groups despite pair feedings.  There was a significant reduction in uterine weight in 
the OVX groups indicating success of ovariectomy.  Blueberry did not induce an increase 
in uterine weight. There was no significant difference in the weight of liver or spleen 
among treatment groups.   
 
Lipid parameters 
 As we have observed in previous studies (Lucas et al., 2003; Lucas et al., 2004), 
ovariectomy significantly increased serum total and non-HDL cholesterol concentrations 
(Figure 2).  Ovariectomy caused a 35% and 31% increase in total and non-HDL 
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cholesterol, respectively.  The doses of blueberry used in the study were not effective at 
reducing the rise in cholesterol due to ovariectomy.  HDL cholesterol was increased due 
to ovariectomy and blueberry had no effect (Table 3).  There was no significant 




Results of other serum clinical parameters are presented in Table 4.  Alkaline 
phosphatase (P=0.0041) and glucose (P=0.0129) levels increased significantly with 
ovariectomy and blueberry has no effect on these parameters.   Serum phosphorus 
(P=0.0004) and blood urea nitrogen (P=0.0054) levels showed significant decreases with 
ovariectomy, with BB having no significant effect on these parameters.  Serum albumin 
(P<0.0001) and total protein (P=0.0001) decreased significantly with ovariectomy.  
Among the OVX groups, these clinical parameters were highest with the 5% BB diet.  
The serum levels of calcium and creatinine did not differ among groups. 
 
Lipid hydroperoxide 
 Ovariectomy has no effect on serum levels of lipid hydroperoxide (Figure 3).  







Ovariectomy did not cause significant changes in serum isoprostane levels (Figure 
4).  The 8-isoprostane levels appeared to decrease with higher concentrations of 







Serum cholesterol is a major risk factor for the development of CVD.  This study 
investigated whether blueberry was effective at preventing an increase in serum total 
cholesterol in a rat model of postmenopausal hypercholesterolemia.  Blueberry was 
chosen for this study due to its rich antioxidant content.  The total antioxidant capacity of 
blueberry is among the highest of all fruits and vegetables (Ehlenfeldt and Prior, 2001; 
Halvorsen et al., 2002; Roy et al., 2002).  Antioxidants are associated with a decreased 
risk of CVD by preventing the oxidation of cholesterol.  Blueberries have been found to 
increase serum antioxidant status, and therefore may help prevent the development of 
cardiovascular disease (Kay and Holub, 2002). 
Blueberries also contain polyphenols such as anthocyanins, resveratrol, and 
pterostilbene.  An increased intake of polyphenols may improve cholesterol and reduce 
CVD risk (American Dietetic Association, 2005; American Heart Association, 2007).  
Previous studies have shown that blueberries may have the ability to prevent heart 
disease, cancer, and improve neural motor function in the aging (Joseph et al., 1999).    
Blueberry is also a source of soluble fiber which is associated with lower 
cholesterol and improved blood glucose and insulin levels (Marlett et al., 2002; Galisteo 
et al., 2008) and has also been found to improve other metabolic syndrome abnormalities 
 36 
including hypertension (Behall et al., 2006), weight control, and improved insulin 
sensitivity (Galisteo et al., 2008).  
Unfortunately, the results of this study did not find blueberries to have 
cholesterol lowering properties.  However, other studies looking at oxidative 
biomarkers have found cardiac benefits without improvements to the lipid profile.   
Devaraj and colleagues (2007) found that supplementation with the antioxidant 
vitamin E did not alter lipid profile but did significantly reduce LDL oxidation 
(Devaraj et al., 2007).  In another study, participants consuming antioxidant rich 
tomatoes showed a significant decrease in lipid peroxidation rate but there were no 
significant changes in lipid profile (Bose and Agrawal, 2007).   Therefore, we 
determined that oxidative biomarkers should be investigated in this study due to 
blueberry’s high antioxidant content.  However, in this study, blueberry consumption 
unexpectedly tended to increase serum lipid hydroperoxide and had no significant 
effect on 8-isoprostane levels.  These findings were surprising considering blueberry’s 
high antioxidant capacity.   
A possible reason why this study had unexpected findings is that the quantity and 
quality of polyphenols were not measured prior to this study.  Although blueberries are 
recognized for their high antioxidant and phenolic content, we are uncertain of the 
phenolic content of the blueberries used in this study.   
In this study, an ovariectomized rat model was used.  Although this animal model 
is economical and well suited for a joint study on bone loss, the golden Syrian hamster 
may be a better model.   Ovariectomized hamsters experience changes in lipids 
comparable to postmenopausal women which make them an appropriate model for 
 37 
studying cholesterol metabolism (Sohn et al., 1999).      
It would be interesting to see if this study would have had different results if a 
greater amount of blueberry had been used.  In this study, treatment groups consisted of 
2.5%, 5%, and 7.5% blueberry.  However, other studies involving blueberry have found 
benefits with greater doses.  In a study which found that blueberries can alter the 
composition and structure of the rat aorta, treatment consisted of an 8.0% blueberry 
enriched diet (Kalea et al., 2006).  Additionally, in a study investigating the effects of 
blueberry on ischemia-induced brain damage, Sweeny and colleagues (2002) determined 
that the consumption of a 14.3% blueberry diet may help protect against ischemia-
induced brain damage, and may help improve stroke outcomes.   
Although the above studies did not investigate the effects of blueberry on lipid 
parameters, studies with similar dietary modifications have shown lipid profile 
improvements with higher treatment doses than this current study.  Experimental diets of 
12% strawberry and plum powder have resulted in a significant decrease in serum and 
liver cholesterol in a rat model (Mateos et al., 2005).  Cocoa powder, which is a rich 
source of polyphenols and fiber, has resulted in significant cholesterol reductions at both 
12% (Mateos  et al., 2005) and 16.5% (Lecumberri et al., 2007).    
In summary, dietary modifications play an important role in reducing cholesterol 
and other CVD risk factors.  Diets rich in antioxidants from fruits and vegetables have 
been associated with a decreased risk of CVD.  Soluble fiber and phytoestrogens have 
also been vastly studied for their potential to reduce cholesterol and CVD risk.  The need 
for dietary alternatives is especially important for postmenopausal women considering 
the side effects of HRT and cholesterol lowering medications.  Although this current 
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study did not find improvements to the lipid profile of ovariectomized rats, there is a need 
for further studies of blueberries due to their rich antioxidant and phenolic 






















Figure 1:  Experimental Design 
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Figure 2:  The effects of the 90 day intake of three doses of blueberry (BB) on serum 




¹ Values are means ± standard errors of the mean, n = 12 or 13 per group. 
² Bars that do not share the same superscript letters are significantly (P < 0.05) different 
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Figure 3:  The effects of the 90 day intake of three doses of blueberry (BB) on serum 
levels of lipid hydroperoxide (LPO) of ovariectomized (OVX) rats ¹ 
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Figure 4:  The effects of the 90 day intake of three doses of blueberry (BB) on serum 
levels of 8-isoprostane of ovariectomized (OVX) rats ¹ 
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Table 1: Composition of the experimental diet 
The composition of these experimental diets was based on the AIN-93M (Harlan Teklad; Madison,WI).  
†The vitamin mixture (TD #94047) obtained from Harlan Teklad (Madison, WI) consisted of (g/kg): nicotinic 
acid, 3.0; calcium pantothenate, 1.6; pyridoxine HCl, 0.7; thiamin HCl, 0.6; riboflavin, 0.6; folic acid, 0.2; D-
biotin, 0.02; vitamin B-12 (0.1% mannitol), 2.5; DL-_-tocopheryl acetate (500 IU/g), 15; vitamin A palmitate 
(500,000IU/g), 0.8; cholecalciferol (500,000 IU/g), 0.2; phylloquinone, 0.075; and sucrose,974.705. 
‡The mineral mixture (TD #79055) obtained from Harlan Teklad (Madison, WI) was a modification of the 
AIN 76 lacking calcium and phosphorus but with sucrose as a diluent. 
 








Blueberry 0 0 25 50 75 
      
Carbohydrate      
Total 720.7 720.7 720.7 720.7 720.7 
Cornstarch 466 466 443.6 421.5 399.4 
Sucrose 100 100 100 100 100 
Dextrinized Corn Starch 155 155 155 155 155 
Blueberry provides 88.4% carbohydrate 0 0 22.1 44.2 66.3 
      
Protein      
Total 140 140 140 140 140 
Casein 140 140 139.1 138.2 137.3 
Blueberry 3.53% protein 0 0 0.9 1.8 2.7 
      
Fat      
Total 40 40 40 40 40 
Soybean Oil 40 40 39.5 39 38.5 
Blueberry provides 1.91% fat 0 0 0.5 1 1.5 
      
Fiber      
Total 50 50 50 50 50 
Cellulose 50 50 48.9 47.8 46.7 
Blueberry provides 4.32% fiber 0 0 1.1 2.2 3.3 
      
Vitamin Mix (AIN 93VX)† 10 10 10 10 10 
      
Mineral Mix‡      
Total 37.5 37.5 37.5 37.5 37.5 
Mineral Mix (Ca-P Def) 13.4 13.4 13.4 13.4 13.4 
Calcium Carbonate 10 10 9.9 9.8 9.8 
Blueberry provides 0.12% calcium   0.03 0.06 0.09 
Potassium Phosphate, monobasic  (KH2PO4) 13.2 13.2 13 12.9 12.6 
Blueberry provides 0.10% phosphorus   0.025 0.05 0.075 
Potassium Citrate 0.9 0.9 0.9 0.9 0.9 
Sucrose 0 0 0.2 0.4 0.6 
      
Choline Bitartrate 2.5 2.5 2.5 2.5 2.5 
L-cysteine 1.8 1.8 1.8 1.8 1.8 
Tert-butylhydroquinone 0.008 0.008 0.008 0.008 0.008 
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Table 2: The effects of three doses of blueberry (BB) on food intake and body and organ weights of  
ovariectomized (OVX) rats ¹,² 
 
 
¹ Values are means ± standard errors of the mean, n = 12 or 13 per group. 
² Within a row, values that do not share the same superscript letters are significantly (P < 











 Sham Ovx  
Blueberry 0 0 2.5% 5% 7.5% P value 
Average food intake 
(g/day) 
13.7 ± 0.29 13.9 ± 0.29 13.9 ± 0.29 14 ± 0.29 14.0 ± 0.29 0.9652 
Body weights (g)       
Initial 247.5 ± 4.4 247.9 ± 4.4 249.4 ± 4.3 248.9 ± 4.4 249.37 ± 4.3 0.9968 
Final 283.9 ± 5.6b 320.0 ± 5.6a 317.1 ± 5.4a 321.3 ± 5.6a 319.9 ± 5.4a <0.0001 
Uterus (g)  0.54 ± 0.02a 0.13 ± 0.02b 0.14 ± 0.02b 0.15 ± 0.02b 0.14 ± 0.02b <0.0001 
Liver (g) 6.10 ± 0.14 5.99 ± 0.14 5.91 ± 0.14 6.07 ± 0.14 6.12 ± 0.14 0.8144 
Spleen (g)  0.76 ± 0.03 0.73 ± 0.03 0.73 ± 0.03 0.72 ± 0.03 0.73 ± 0.03 0.9262 
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Table 3:  The effects of the 90 day intake of three doses of blueberry (BB) on serum and 
hepatic lipid parameters of ovariectomized (OVX) rats ¹,² 
 





Blueberry 0 0 2.5% 5% 7.5% P value 
Serum lipids  
Triglycerides 
(mg/dL) 
48.0 ± 2.3 52.7 ± 2.3 52.5 ± 2.2 53.0 ± 2.3 53.2 ± 2.2 0.4668 
HDL_Cholesterol 
(mg/dL) 
30.8 ± 1.5b 44.0 ± 1.5a 46.3 ± 1.4a 44.5 ± 1.5a 47.5 ± 1.4a <0.0001 
Liver lipids  
Total lipid 
(mg/g liver) 
58.6 ± 1.5    59.5 ± 1.5  56.3 ± 1.5  55.6 ± 1.5   56.2 ± 1.5    0.3080 
Cholesterol 
(mg/g liver) 
3.46 ± 0.23 3.60 ± 0.23 3.03 ± 0.22 3.29 ± 0.23 3.20 ± 0.22 0.4457 
 
¹ Values are means ± standard errors of the mean, n = 12 or 13 per group. 
 
² Within a row, values that do not share the same superscript letters are significantly (P < 












Table 4:  The effects of the 90 day intake of three doses of blueberry (BB) on serum 














35.3 ± 3.0b 44.2 ± 3.0a 48.7 ± 2.9a 50.4 ± 3.0a 49.6 ± 2.9a 0.0041 
Phosphorus, mg/dL 4.9 ± 0.14a 4.0 ± 0.14b 4.2 ± 0.14b 4.1 ± 0.14b 4.2 ± 0.14b 0.0004 
Calcium, mg/dL 10.0 ± 0.08 9.7 ± 0.08 9.7 ± 0.07 9.7 ± 0.08 9.7 ± 0.07 0.0661 
Glucose, mg/dL 154.4 ± 6.9b 188.8 ± 6.9a 173.7± 6.7a 180.1± 6.9a 180.2± 6.7a 0.0129 
Blood urea nitrogen, 
mg/dL 
16.4 ± 0.66a 13.5 ± 0.66b 14.0± 0.63b 12.9± 0.66b 14.0± 0.63b 0.0054 
Creatinine, mg/dL 0.59 ± 0.02 0.60 ± 0.02 0.55 ± 0.02 0.59 ± 0.02 0.61 ± 0.02 0.4521 
Albumin, g/dL 3.5 ± 0.03a 3.2 ± 0.03bc 3.1 ± 0.03c 3.3 ± 0.03b 3.2 ± 0.03c <0.0001 
Total Protein, g/dL 6.9 ± 0.06a 6.6 ± 0.06bc 6.5 ± 0.06c 6.8± 0.06ab 6.7 ± 0.06b 0.0001 
 
¹ Values are means ± standard errors of the mean, n = 12 or 13 per group. 
² Within a row, values that do not share the same superscript letters are significantly (P < 
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Scope and Method of Study:  
Cardiovascular disease (CVD) is a leading cause of death in the nation with an associated 
annual health care cost of approximately $448 billion. In women, risk for CVD 
drastically increases when they reach menopause, partly due to elevation of cholesterol. 
With the side effects associated with hormone replacement therapy and other prescription 
medications, dietary modifications play an important role in reducing cholesterol and 
other CVD risk factors in postmenopausal women.  This study examines the effects of 
blueberry (BB) on modulating lipid profile in ovariectomized (Ovx) rats.  Blueberry is a 
rich source of phenolic compounds and has a high antioxidant capacity.  Sixty-two five-
month old female Sprague-Dawley rats were either sham-operated (Sham) or Ovx and 
randomly assigned to one of five treatment groups (n=12-13/group), Sham +control, Ovx 
+control, Ovx+ 2.5% BB, Ovx +5.0% BB, or Ovx +7.5%BB.   
Findings and Conclusions:   
 
After 90 days of treatment, rats were necropsied and tissue samples were collected. Total 
cholesterol increased due to Ovx but none of the doses of BB were able to prevent the 
Ovx- induced rise in serum total cholesterol. Triglycerides and liver cholesterol were not 
altered by Ovx or dietary treatment. The results of this study indicate that the 
hypercholesterolemic effects of ovariectomy are not prevented by BB.   
